Moderna's mRESVIA became the first approved mRNA vaccine for respiratory syncytial virus in adults 60+, a milestone in vaccine technology.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
COVID Was Just the Start: What’s Next for mRNA?
MRESVIA Approved First mRNA RSV vaccine
60+ Adults years Target population
Tetravalent In Trials Flu vaccines
2025 Approval year
60+ Years adults
Clinical Trials flu vaccines